建科院 reported revenue of ¥0.10B for the period ended 2026-06-30, -11.3% year on year. Net income was ¥-0.02B, a -20.4% net margin on a 25.5% gross margin. The largest revenue line is 公信服务 at 37% of the total. Free cash flow for the period was ¥-0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.10B | -11.3% |
| Gross profit | ¥0.03B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | — |
| Gross margin | 25.5% | Net margin -20.4% |
| Revenue Q/Q | +21.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 公信服务 | ¥0.04B | 36.7% |
| 场景创新服务 | ¥0.03B | 32.6% |
| 其他技术服务 | ¥0.03B | 24.5% |
| 战略孵化服务 | ¥0.01B | 6.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.08B | 74.5% |
| R&D | ¥0.01B | 11.7% |
| SG&A | ¥0.03B | 26.7% |
| Tax & other | ¥0.00B | 1.0% |
| Item | Amount |
|---|---|
| Total assets | ¥1.30B |
| Total liabilities | ¥0.79B |
| Shareholders' equity | ¥0.52B |
| Equity / assets | 39.7% |
| Operating cash flow | ¥-0.00B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.00B |
| Cash conversion (OCF / net income) | 85% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
华大基因 ・ 英科医疗 ・ 中科信息 ・ 电连技术 ・ 隆盛科技 ・ 英搏尔 ・ 朗新科技 ・ 海特生物 ・ 中石科技 ・ 艾德生物 ・ 智动力 ・ 赛意信息
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies